MedTrace Logo

To Assess the Efficacy of Carica Papaya Leaf Extract in Improving Platelet Counts Among Pediatric Patients With Dengue-associated Thrombocytopenia

NCT07172100 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-09-15

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate whether Carica papaya leaf extract (CPLE) can improve platelet counts in children aged 2 to 12 years diagnosed with dengue fever and thrombocytopenia. The main questions it aims to answer are:

Does Carica papaya leaf extract significantly increase platelet counts compared to standard supportive therapy alone?

Does the use of Carica papaya leaf extract reduce the need for platelet transfusion or PICU admission?

Researchers will compare the group receiving CPLE plus standard therapy to the group receiving standard therapy alone to see if CPLE leads to improved platelet recovery and better clinical outcomes.

Participants will:

Be randomly assigned to receive either standard care or standard care plus Carica papaya leaf extract syrup (10 mL orally, three times daily for 3 days)

Undergo blood testing on Day 1 and Day 3 to assess platelet count, hemoglobin, WBC, and packed cell volume

Be monitored for clinical outcomes including need for transfusion and admission to the Pediatric Intensive Care Unit (PICU)

Conditions

  • Dengue Fever
  • Papaya Leaf Extract
  • Pediatric Patients

Interventions

DRUG

Carica Papaya Leaf Extract Group

Carica papaya leaf extract syrup will be administered orally at a dose of 10 mL three times daily (TID) for a total of 3 days. Each 10 mL dose contains 1000 mg of papaya leaf extract. This intervention will be given in addition to standard supportive therapy for dengue fever

OTHER

standard treatment

patients in this group will receive only the standard treatment for dengue fever

Sponsors & Collaborators

  • Ziauddin Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2025-11-30
Completion
2025-12-01

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07172100 on ClinicalTrials.gov